fam92a Antibody

What is FAM92A1 and what are its key cellular functions?

FAM92A1 is a ubiquitously expressed mitochondrial membrane-bound protein localized to the matrix side of the mitochondrial inner membrane (MIM). It contains a BAR (Bin/amphiphysin/Rvs) domain that facilitates membrane binding and remodeling. FAM92A1 serves two primary functions: (1) maintaining mitochondrial function including membrane potential, oxygen consumption rate, and ATP production; and (2) participating in ciliogenesis through interaction with Chibby1 protein . Loss-of-function experiments demonstrate that FAM92A1 depletion results in defective cell proliferation, diminished mitochondrial membrane potential, increased oxidative stress, and decreased cellular oxygen consumption rate, indicating its fundamental importance for cellular metabolism .

What is the molecular structure and localization pattern of FAM92A1?

FAM92A1 is a 289 amino acid protein with a calculated molecular weight of 33 kDa, though it typically appears at 29-33 kDa on immunoblots. The protein harbors a conserved N-terminal sequence (first 47 amino acids) consisting of alternating hydrophobic and positively charged amino acids, characteristic of a mitochondrial import presequence. This N-terminal peptide is essential and sufficient for mitochondrial targeting and is cleaved after import. FAM92A1 also contains a BAR domain that facilitates membrane curvature generation and preferentially binds to negatively charged phospholipids, particularly cardiolipin which is abundant in the mitochondrial inner membrane . Immunofluorescence studies show FAM92A1 localizes to both mitochondria and the mother centrioles/basal bodies of primary cilia, reflecting its dual functionality .

How does FAM92A1 interact with membranes?

FAM92A1 directly interacts with membranes through its BAR domain, with enhanced binding to negatively charged phospholipids such as phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) and cardiolipin. This interaction follows a characteristic pattern observed in other BAR domain proteins. Biochemical studies using 1,6-diphenyl-1,3,5-hexatriene (DPH) anisotropy show that FAM92A1 not only binds to but also inserts into the hydrophobic region of the lipid bilayer, with the N-terminal peptide facilitating this insertion before its cleavage. The membrane association is significant for its function in membrane remodeling processes during both mitochondrial dynamics and ciliogenesis . Experimental evidence shows that deletion of the first 40 amino acids results in reduced membrane binding affinity but does not completely abolish it, suggesting multiple membrane interaction sites exist within the protein .

What types of FAM92A1 antibodies are available for research?

Several FAM92A1 antibodies are available for research applications, with Proteintech's 24803-1-AP being a well-characterized example. This is a rabbit polyclonal antibody raised against FAM92A1 fusion protein (Ag20738). In addition to commercial options, literature reports the use of antibodies such as anti-FAM92A1 (HPA034760; Sigma-Aldrich) . When selecting an antibody, researchers should consider factors such as host species (typically rabbit), clonality (polyclonal vs monoclonal), validated applications (WB, IP, IHC, IF/ICC), and documented specificity through knockdown or knockout validation. For dual labeling experiments, antibody compatibility with other primary antibodies is essential to avoid cross-reactivity issues .

How should researchers validate FAM92A1 antibody specificity?

Proper validation of FAM92A1 antibody specificity is crucial for accurate data interpretation. A comprehensive validation approach should include:

• Knockdown/knockout controls: siRNA or shRNA-mediated FAM92A1 depletion should show reduced signal intensity proportional to the knockdown efficiency .

• Overexpression controls: Compare antibody detection of endogenous protein with ectopically expressed tagged versions (such as GFP-tagged or Flag-tagged FAM92A1) .

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight (29-33 kDa for endogenous FAM92A1, ~34 kDa for His-tagged recombinant protein) .

• Cross-reactivity assessment: Test for potential cross-reactivity with related family members like FAM92B, especially in tissues or cell lines where both proteins are expressed .

• Subcellular localization correlation: Verify that the immunofluorescence signal colocalizes with known mitochondrial markers (like TOM20) and centriolar/basal body markers (like CEP164) in appropriate experimental contexts .

What are the optimal working conditions for FAM92A1 antibodies in various applications?

Based on validated protocols and published literature, these are the recommended working conditions for FAM92A1 antibodies:

For double labeling with other rabbit antibodies (like CEP164), sequential staining protocols have been developed. Researchers should also note that sample-dependent optimization may be necessary, particularly for challenging applications like mitochondrial protein detection .

How should researchers design FAM92A1 knockdown experiments?

For effective FAM92A1 knockdown studies, researchers should consider:

• siRNA design: Two validated siRNA target sequences for human FAM92A1 are: (i) 5′-GGATCAACAAGCAGAAGAT-3′ (positions 801-819) and (ii) 5′-GCAGAAACGGAATTACAGA-3′ (positions 439-457) . Design experiments with at least two independent siRNAs to control for off-target effects.

• Cell type selection: RPE1 cells have been successfully used for FAM92A1 knockdown studies, particularly for ciliogenesis experiments. HeLa cells are suitable for mitochondrial function studies .

• Transfection optimization: Different cell types require optimized transfection protocols; lipid-based transfection works well for RPE1 and HeLa cells.

• Knockdown validation: Confirm knockdown efficiency at both protein level (western blot) and mRNA level (qRT-PCR).

• Rescue experiments: Include rescue controls with siRNA-resistant FAM92A1 constructs to confirm phenotype specificity.

• Phenotypic assays: For mitochondrial function, measure membrane potential, OCR, ATP production, and ROS levels. For ciliogenesis, examine cilia formation after serum starvation (48h) using acetylated α-tubulin staining .

What protocols are recommended for studying FAM92A1 localization in cells?

For optimal visualization of FAM92A1 subcellular localization:

• Fixation method: Cold methanol fixation is preferred for both mitochondrial and centrosomal localization studies. For MTECs (mouse tracheal epithelial cells), methanol-acetone (1:1) fixation has been effective .

• Permeabilization: Brief treatment with 0.2% Triton X-100 if using paraformaldehyde fixation.

• Blocking: 3-5% BSA or normal serum (matching secondary antibody host) for 1 hour at room temperature.

• Primary antibody: Incubate with anti-FAM92A1 (1:200-1:800) overnight at 4°C.

• Co-staining markers:

  • For mitochondrial localization: anti-TOM20 (1:500), anti-COXIV (1:500), or MitoTracker dyes

  • For centriole/basal body localization: anti-γ-tubulin (1:500), anti-CEP164 (1:500), anti-acetylated α-tubulin (1:500)

• Sequential staining: For double-labeling with rabbit antibodies, perform sequential staining with intermediate image acquisition .

• Advanced imaging: Super-resolution microscopy (SIM or STED) can provide better resolution of FAM92A1 localization at the mitochondrial inner membrane and centriolar structures .

How can researchers effectively analyze FAM92A1's role in mitochondrial function?

To comprehensively analyze FAM92A1's role in mitochondrial function, researchers should employ multiple complementary approaches:

• Mitochondrial membrane potential: Use JC-1 or TMRM dyes with flow cytometry or live-cell imaging quantification.

• Oxidative stress assessment: Measure ROS levels in mitochondria and cytoplasm using MitoSOX and DCF-DA, respectively.

• Respiration analysis: Measure oxygen consumption rate (OCR) using a Seahorse XF Analyzer to assess basal respiration, ATP production, maximal respiration, and spare respiratory capacity.

• ATP production: Quantify cellular ATP levels using luciferase-based assays.

• Electron transport chain analysis: Assess complex assembly and enzyme activities, particularly complexes I and IV, using blue native PAGE and in-gel activity assays.

• Mitochondrial morphology: Examine mitochondrial network structure using confocal microscopy after staining with mitochondrial markers.

• Cell growth comparison: Compare growth rates in glucose versus galactose-containing media to assess dependence on mitochondrial function.

These assays should be performed in both control and FAM92A1-depleted cells, with rescue experiments using wild-type FAM92A1 to confirm specificity of observed phenotypes .

How does FAM92A1 contribute to membrane remodeling in mitochondria and cilia?

FAM92A1's BAR domain confers the ability to sense and induce membrane curvature, a property shared by other BAR domain proteins. In mitochondria, FAM92A1 preferentially binds to cardiolipin-rich membranes of the inner mitochondrial membrane and may participate in cristae organization. Experimental evidence shows that FAM92A1 not only binds to but also inserts into the hydrophobic region of lipid bilayers, particularly those with mitochondrial lipid composition. This membrane-remodeling activity likely contributes to maintaining proper mitochondrial ultrastructure .

In the context of ciliogenesis, FAM92A1 cooperates with Chibby1 to potentially regulate membrane dynamics at the ciliary base. When co-expressed, FAM92A1 and Cby1 can induce deformed membrane-like structures containing the small GTPase Rab8, suggesting a role in vesicle trafficking or membrane remodeling during cilia formation. Advanced imaging techniques such as electron microscopy combined with immunogold labeling could further elucidate the precise membrane-remodeling functions of FAM92A1 at both mitochondria and cilia .

What are the differences between FAM92A1 and FAM92B in functionality and expression?

While both FAM92A1 and FAM92B contain BAR domains and interact with Chibby1, they show distinct expression patterns and potentially specialized functions:

• Expression patterns: FAM92A1 appears to be the predominant family member in human retinal pigment epithelial (RPE1) cells, while FAM92B expression may be more tissue-restricted.

• Subcellular localization: Both proteins localize to mother centrioles/basal bodies of cilia, but FAM92A1 has an additional mitochondrial localization mediated by its N-terminal targeting sequence.

• Protein interactions: Both interact with Chibby1 via their BAR domains and can form homo- and heterodimers.

• Functional redundancy: In ciliogenesis, there may be partial functional redundancy, but the unique mitochondrial localization of FAM92A1 suggests distinct roles.

• Membrane binding: While both contain BAR domains that associate with membranes, differences in lipid binding preferences or membrane remodeling capabilities have not been fully characterized.

Future research using comparative proteomics, domain-swapping experiments, and tissue-specific knockout models could further elucidate the specialized functions of these related family members .

What is known about the role of FAM92A1 in disease contexts?

While research on FAM92A1's role in disease is still emerging, several lines of evidence suggest potential disease relevance:

• Mitochondrial disorders: Given FAM92A1's critical role in mitochondrial function, including respiratory chain complex assembly and activity, its dysfunction may contribute to mitochondrial disease phenotypes. Particular attention should be given to disorders affecting complex I and IV activities.

• Ciliopathies: As FAM92A1 knockdown impairs ciliogenesis, it may play a role in ciliopathies – a diverse group of disorders caused by defects in primary cilia structure or function, including polycystic kidney disease, retinal degeneration, and developmental anomalies.

• Cancer: The protein has been detected in human renal cell carcinoma tissue by immunohistochemistry, suggesting potential involvement in cancer pathways. Its role in regulating cellular energy metabolism could influence cancer cell proliferation and survival.

• Oxidative stress-related conditions: FAM92A1 depletion increases oxidative stress, which is implicated in neurodegenerative diseases, aging, and various chronic disorders.

Researchers investigating disease relevance should consider FAM92A1 expression levels, potential mutations, or post-translational modifications in relevant patient samples or disease models .

What are common challenges when working with FAM92A1 antibodies and how can they be addressed?

Researchers frequently encounter these challenges when working with FAM92A1 antibodies:

• Cross-reactivity with FAM92B: Validate antibody specificity using FAM92A1 knockdown cells. Consider immunoprecipitation followed by mass spectrometry to confirm antibody targets.

• Weak mitochondrial signal in immunofluorescence: Optimize fixation (cold methanol works best), permeabilization conditions, and antibody concentration. Consider signal amplification systems for low-abundance targets.

• Multiple bands in western blots: This may represent different isoforms, post-translational modifications, or proteolytic fragments. Include positive controls (recombinant protein) and negative controls (knockdown samples) for band identification.

• Inconsistent results across cell types: FAM92A1 expression levels vary across cell types; optimize antibody dilution for each cell line. Consider enriching mitochondrial fractions for better detection of mitochondrial proteins.

• Double-labeling difficulties: For co-staining with other rabbit antibodies (like CEP164), use sequential staining with intermediate image acquisition to avoid cross-reactivity, as demonstrated in published protocols .

What methodological approaches can be used to study the interaction between FAM92A1 and membrane lipids?

To investigate FAM92A1-membrane interactions, researchers can employ these methodological approaches:

• Liposome binding assays: Create liposomes with defined lipid compositions (PC:PE, with or without cardiolipin or PI(4,5)P₂) and assess FAM92A1 binding through co-sedimentation assays.

• DPH anisotropy measurements: Quantify changes in 1,6-diphenyl-1,3,5-hexatriene (DPH) anisotropy to assess protein insertion into the hydrophobic region of lipid bilayers.

• Lipid strip assays: Test binding preferences to different phospholipids immobilized on membrane strips.

• FRET-based approaches: Label FAM92A1 and liposomes with appropriate fluorophores to measure interaction dynamics in real-time.

• Microscopy techniques:

  • Fluorescence microscopy of GFP-tagged FAM92A1 with fluorescent lipid probes

  • Electron microscopy to visualize membrane deformation induced by FAM92A1

• Structure-function analysis: Test binding properties of wild-type FAM92A1 versus mutants affecting the BAR domain or the N-terminal presequence.

• In silico modeling: Use molecular dynamics simulations to predict membrane interaction sites and conformational changes.

These approaches have demonstrated that FAM92A1 preferentially binds to negatively charged phospholipids and can insert into membranes, with enhanced interaction with cardiolipin-containing membranes .

How can researchers investigate the dual function of FAM92A1 in both mitochondria and cilia?

Investigating FAM92A1's dual functionality requires specialized experimental approaches:

• Domain-specific mutants:

  • Generate constructs lacking the N-terminal mitochondrial targeting sequence (Δ1-47) to specifically disrupt mitochondrial localization

  • Create BAR domain mutants to affect membrane binding and curvature sensing

  • Test these constructs in rescue experiments to dissect function-specific roles

• Temporal analysis:

  • Use synchronized cell populations to examine FAM92A1 localization and function throughout the cell cycle

  • Track protein dynamics during ciliogenesis using live-cell imaging with fluorescently tagged FAM92A1

• Proximity labeling:

  • Apply BioID or APEX2 proximity labeling to identify location-specific interaction partners in mitochondria versus centrioles/basal bodies

  • Compare interactomes to identify organelle-specific functions

• Functional uncoupling:

  • Design FAM92A1 variants with organelle-specific targeting (e.g., strengthened mitochondrial targeting or centriole-specific localization)

  • Express these variants in FAM92A1-depleted cells to determine which functions can be separated

• Tissue-specific analysis:

  • Compare FAM92A1 function in cell types with varying dependence on mitochondrial function and ciliogenesis

  • Examine tissues from model organisms with tissue-specific FAM92A1 manipulation

These approaches will help elucidate whether FAM92A1's dual localization represents truly independent functions or an integrated cellular role connecting mitochondrial function and ciliogenesis .